Journal
THORAX
Volume 67, Issue 8, Pages 754-756Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2012-201869
Keywords
-
Categories
Funding
- Astra Zeneca
- GlaxoSmithKline
- Novartis
- Medimmune
- HSC RD (NI)
- Wellcome Senior Clinical Fellowship
- AZ
- Amgen
- Chiesi, BI
- Roche
- Genentech
- Merck Sharpe Dohme
- Nycomed
- Medical Research Council [G1000758B, G1000758] Funding Source: researchfish
Ask authors/readers for more resources
Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available